Yvonne Paterson
1. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.Kim SH, Castro F, Paterson Y, ...Gravekamp C
Cancer Res. 2009 Jul 15. 69(14): 5860-6
2. Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.
Mustafa W, Maciag PC, Pan ZK, ...Weaver JR, Xiao Y, Isaacs SN, Paterson Y
Viral Immunol. 2009 Jun. 22(3): 195-204
3. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.
Seavey MM, Maciag PC, Al-Rawi N, ...Sewell D, Paterson Y
J Immunol. 2009 May 1. 182(9): 5537-46
4. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
Wallecha A, Carroll KD, Maciag PC, ...Rivera S, Shahabi V, Paterson Y
Adv Appl Microbiol. 2009. 66: 1-27
5. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
Seavey MM, Pan ZK, Maciag PC, ...Wallecha A, Rivera S, Paterson Y, Shahabi V
Clin Cancer Res. 2009 Feb 1. 15(3): 924-32
6. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.
Wallecha A, Maciag PC, Rivera S, ...Paterson Y, Shahabi V
Clin Vaccine Immunol. 2009 Jan. 16(1): 96-103
7. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.
Wood LM, Guirnalda PD, Seavey MM, ...Paterson Y
Immunol Res. 2008. 42(1-3): 233-45
8. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.
Kim SH, Castro F, Gonzalez D, ...Maciag PC, Paterson Y, Gravekamp C
Br J Cancer. 2008 Sep 2. 99(5): 741-9
9. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.
Sewell DA, Pan ZK, Paterson Y
Vaccine. 2008 Sep 26. 26(41): 5315-20
10. Development of a Listeria monocytogenes based vaccine against prostate cancer.
Shahabi V, Reyes-Reyes M, Wallecha A, ...Rivera S, Paterson Y, Maciag P
Cancer Immunol Immunother. 2008 Sep. 57(9): 1301-13
11. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.
Souders NC, Sewell DA, Pan ZK, ...Hussain SF, Rodriguez A, Wallecha A, Paterson Y
Cancer Immun. 2007 Feb 6. 7: 2
12. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
Singh R, Paterson Y
Cancer Immunol Immunother. 2007 Jun. 56(6): 927-38
13. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy.
Peng X, Treml J, Paterson Y
Cancer Immunol Immunother. 2007 Jun. 56(6): 797-806
14. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.
Singh R, Paterson Y
Expert Rev Vaccines. 2006 Aug. 5(4): 541-52
15. A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype.
Neeson P, Boyer J, Kumar S, ...Lewis MG, Mattias L, Veazey R, Weiner D, Paterson Y
Virology. 2006 Oct 25. 354(2): 299-315
16. In vivo bactofection: listeria can function as a DNA-cancer vaccine.
Souders NC, Verch T, Paterson Y
DNA Cell Biol. 2006 Mar. 25(3): 142-51
17. Listeria-based vaccines for cancer treatment.
Paterson Y, Maciag PC
Curr Opin Mol Ther. 2005 Oct. 7(5): 454-60
18. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R, Dominiecki ME, Jaffee EM, ...Paterson Y
J Immunol. 2005 Sep 15. 175(6): 3663-73
19. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.
Boyer JD, Robinson TM, Maciag PC, ...Peng X, Johnson RS, Pavlakis G, Lewis MG, Shen A, Siliciano R, Brown CR, Weiner DB, Paterson Y
Virology. 2005 Mar 1. 333(1): 88-101
20. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors.
Hussain SF, Paterson Y
Cancer Immunol Immunother. 2005 Jun. 54(6): 577-86
